Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$44.81 +3.9%	$33.65	$21.97 ▼ $45.07	$2.12B	1.64	590,338 shs	661,049 shs
AVNS Avanos Medical	$11.69 +4.7%	$11.66	$9.30 ▼ $25.36	$543.37M	1.12	795,838 shs	465,995 shs
ENOV Enovis	$31.41 +6.5%	$30.06	$25.47 ▼ $49.83	$1.80B	1.7	1.22 million shs	908,166 shs
EYE National Vision	$24.83 +3.3%	$24.00	$9.56 ▼ $25.67	$1.97B	1.27	2.23 million shs	2.66 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	0.00%	+4.75%	+44.17%	+56.47%	+76.71%
AVNS Avanos Medical	0.00%	+4.55%	-1.76%	-5.08%	-49.64%
ENOV Enovis	0.00%	+6.25%	+15.66%	-0.64%	-29.26%
EYE National Vision	0.00%	+9.24%	-2.01%	+31.72%	+134.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	3.5778 of 5 stars	2.5	5.0	0.0	3.3	2.5	1.9
AVNS Avanos Medical	3.2831 of 5 stars	0.0	3.0	0.0	3.2	3.3	2.5
ENOV Enovis	4.4802 of 5 stars	4.5	3.0	0.0	3.5	3.3	1.9
EYE National Vision	2.7859 of 5 stars	2.3	2.0	3.3	3.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.00	Buy	$40.63	-9.33% Downside
AVNS Avanos Medical	2.00	Hold	N/A	N/A
ENOV Enovis	3.00	Buy	$51.00	62.38% Upside
EYE National Vision	2.60	Moderate Buy	$24.73	-0.41% Downside

Current Analyst Ratings Breakdown

Latest AVNS, AORT, EYE, and ENOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $50.00
8/13/2025	AORT Artivion	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $38.80
8/12/2025	AVNS Avanos Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	AORT Artivion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/8/2025	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $41.00
8/8/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $42.00
8/8/2025	AORT Artivion	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $40.00
8/8/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $45.00
8/8/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $58.00
8/8/2025	ENOV Enovis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $57.00
8/8/2025	ENOV Enovis	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$48.00 ➝ $41.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$388.54M	5.44	$0.83 per share	53.73	$8.90 per share	5.04
AVNS Avanos Medical	$687.80M	0.79	$11.81 per share	0.99	$16.73 per share	0.70
ENOV Enovis	$2.11B	0.85	$19.15 per share	1.64	$45.15 per share	0.70
EYE National Vision	$1.82B	1.08	$1.64 per share	15.18	$10.74 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$13.36M	-$0.42	N/A	89.63	N/A	-4.43%	5.70%	2.29%	11/6/2025 (Estimated)
AVNS Avanos Medical	-$392.10M	-$10.07	N/A	6.76	N/A	-66.89%	6.16%	4.57%	10/29/2025 (Estimated)
ENOV Enovis	-$825.49M	-$14.25	N/A	9.85	N/A	-37.80%	6.78%	3.73%	11/5/2025 (Estimated)
EYE National Vision	-$28.50M	-$0.18	N/A	91.96	2.93	-0.75%	3.56%	1.49%	11/5/2025 (Estimated)

Latest AVNS, AORT, EYE, and ENOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AORT Artivion	$0.11	$0.24	+$0.13	$0.03	$107.96 million	$112.97 million
8/7/2025	Q2 2025	ENOV Enovis	$0.74	$0.79	+$0.05	-$0.64	$555.80 million	$564.50 million
8/6/2025	Q2 2025	EYE National Vision	$0.12	$0.18	+$0.06	$0.11	$469.21 million	$486.42 million
8/5/2025	Q2 2025	AVNS Avanos Medical	$0.18	$0.17	-$0.01	-$1.66	$165.50 million	$175.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
AVNS Avanos Medical	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.52	4.78	3.48
AVNS Avanos Medical	0.12	2.64	1.58
ENOV Enovis	0.53	2.25	1.15
EYE National Vision	0.30	0.52	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
AVNS Avanos Medical	95.17%
ENOV Enovis	98.45%
EYE National Vision	N/A

Insider Ownership

Company	Insider Ownership
AORT Artivion	7.60%
AVNS Avanos Medical	2.64%
ENOV Enovis	2.70%
EYE National Vision	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,600	47.18 million	43.60 million	Optionable
AVNS Avanos Medical	2,227	46.40 million	45.18 million	Optionable
ENOV Enovis	7,367	57.16 million	55.62 million	Optionable
EYE National Vision	13,411	79.20 million	77.06 million	Optionable

AVNS, AORT, EYE, and ENOV Headlines

Recent News About These Companies

It's Still Early For National Vision Holdings

August 24 at 4:00 AM | seekingalpha.com

National Vision Holdings, Inc. $EYE Shares Bought by Charles Schwab Investment Management Inc.

August 24 at 3:18 AM | marketbeat.com

Vanguard Group Inc. Grows Position in National Vision Holdings, Inc. $EYE

August 24 at 3:17 AM | marketbeat.com

Channing Capital Management LLC Takes Position in National Vision Holdings, Inc. $EYE

August 23 at 8:31 AM | marketbeat.com

22,162 Shares in National Vision Holdings, Inc. $EYE Purchased by Fox Run Management L.L.C.

August 22 at 4:16 AM | marketbeat.com

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

August 21 at 7:18 AM | ophthalmologytimes.comO

Public Sector Pension Investment Board Buys 52,820 Shares of National Vision Holdings, Inc. $EYE

August 21 at 3:52 AM | marketbeat.com

National Vision Announces Participation in Goldman Sachs Global Retailing Conference

August 20, 2025 | businesswire.com

America's Best Unveils Major Brand Transformation: VML Relaunches Eye Care Retailer's Identity with the Powerful Message "Every Eye Deserves Better"

August 19, 2025 | prnewswire.com

Burgundy Asset Management Ltd. Raises Stake in National Vision Holdings, Inc. (NASDAQ:EYE)

August 19, 2025 | marketbeat.com

Boston Partners Reduces Stock Position in National Vision Holdings, Inc. (NASDAQ:EYE)

August 18, 2025 | marketbeat.com

Deutsche Bank AG Has $6.38 Million Stock Position in National Vision Holdings, Inc. (NASDAQ:EYE)

August 18, 2025 | marketbeat.com

Kentuckians encouraged to prioritize eye health during National Eye Exam Month in August

August 16, 2025 | nkytribune.comN

National Vision Holdings: Rating Upgrade As Turnaround Strategy Worked

August 15, 2025 | seekingalpha.com

EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up

August 12, 2025 | zacks.com

Headlands Technologies LLC Has $496,000 Holdings in National Vision Holdings, Inc. (NASDAQ:EYE)

August 10, 2025 | marketbeat.com

National Vision (NASDAQ:EYE) Upgraded by Wall Street Zen to Buy Rating

August 10, 2025 | marketbeat.com

Aspirus Health promotes screenings for National Children's Eye Health and Safety Month

August 9, 2025 | wqow.comW

Aspirus Health encourages eye screenings for kids

August 9, 2025 | msn.com

SLC legislators proclaim August as National Eye Exam month

August 8, 2025 | northcountrynow.comN

National Vision (NASDAQ:EYE) Releases FY 2025 Earnings Guidance

August 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVNS, AORT, EYE, and ENOV Company Descriptions

Artivion NYSE:AORT

$44.81 +1.67 (+3.88%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$44.82 +0.01 (+0.01%)

As of 08/22/2025 04:35 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Avanos Medical NYSE:AVNS

$11.69 +0.53 (+4.74%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$11.70 +0.02 (+0.14%)

As of 08/22/2025 06:10 PM Eastern

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Enovis NYSE:ENOV

$31.41 +1.91 (+6.47%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$31.44 +0.04 (+0.12%)

As of 08/22/2025 06:51 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

National Vision NASDAQ:EYE

$24.83 +0.79 (+3.29%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$24.62 -0.20 (-0.83%)

As of 08/22/2025 07:08 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time